Step by Step


5/17/22 - Medical Grand Rounds: Bench to Bedside Series: Targeting Tumor Cell Metabolism to Improve Treatment Outcomes in Metastatic Melanoma





Credit Hours: CME 1.00

Target Audience:

Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.

Educational Objectives:

Upon completion of this activity, participants should be able to:

  • Review the power of the immune system and how it might be employed against early cancers or clinically apparent malignancy
  • Describe how the immune system can fail which allows tumors time to evolve and develop immune evasion adaptations
  • Outline how to extend the benefits of immunotherapy to more patients


This Bench to Bedside Series, features Yana Najjar, MD and Greg Delgoffe, PhD. Dr. Najjar is an assistant professor within the Division of Hematology/Oncology and recipient of numerous awards, including the 2019 junior scholar award for clinical cancer research related to novel immunotherapeutics in advanced melanoma. Dr. Delgoffe is an associate professor in the Department of Immunology, nationally recognized for his research pertaining to the metabolic contributions of T cell (dys)regulation. Together, Drs. Najjar and Delgoffe have identified metabolic targets and subsequent interventions that can improve anti-PD1 checkpoint blockade. We are thrilled to host these leaders in translational research. Please join us for their talk titled, “Targeting Tumor Cell Metabolism to Improve Treatment Outcomes in Metastatic Melanoma"

Suggested Additional Reading & Joint Accreditation Statement - Note: This Accreditation Statement Supersedes All Other Statements:

Suggested additional reading:

  • Scharping et al, Cancer Immunol Res 2017
  • Scharping and Delgoffe, Vaccines 2016
  • Menk, Scharping et al, Cell Reports 2018

Joint Accreditation Statement:

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Pittsburgh School of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit[s]™. Physicians should only claim credit commensurate with the extent of their participation in the activity. This educational activity is approved for 1.0 contact hours.

Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

Greg M. Delgoffe, Ph.D — Associate Professor of Immunology, Director, Tumor Microenvironment Center, University of Pittsburgh
Dr. Delgoffe discloses:
  • Consulting/SAB: BlueSphere Bio, Kalivir, Century Therapeutics, Nanna Therapeutics, Astellas, RemplirBio, and Novasenta
  • Research Support: Kalivir, Century Therapeutics, 2seventybio, Nanna Therapeutics, Astellas, and Novasenta
  • Clinical Trials: Merck, Pfizer, BMS, and Novasenta
  • Founder and Advisor, Equity: RemplirBio, Novasenta
Yana G. Najjar, MD — Assistant Professor of Medicine, Director, Clinical and Translational Research Center, University of Pittsburgh
Dr. Najjar discloses:
  • Consulting/SAB: Merck, Novartis, Venn Bio, Array Biopharma
  • Research Support: Merck, Pfizer, BMS
No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

This activity is approved for AMA PRA Category 1 Credit™

The University of Pittsburgh is an affirmative action, equal opportunity institution.